Skip to content
Reipet – Lifestyle
Author:
Pharmazz, Inc.
Pharmazz Completes Enrollment in 160-Patient Phase 4 Trial of Sovateltide in Acute Ischemic Stroke
September 28, 2026
Pharmazz, Inc. Receives U.S. FDA Orphan Drug Designation for Sovateltide for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE)
September 14, 2026
Pharmazz, Inc. Appoints Ajay Bansal as Chief Financial Officer
May 14, 2026